Eldorado Hotel & Spa Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2019



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Integrated Pathways of Disease in NASH and NAFLD (A4)


Organizer(s) Scott L. Friedman, Arun J. Sanyal, Brent A. Tetri, Mary E. Rinella and Christopher R. Shepard
January 20—24, 2019
Eldorado Hotel & Spa • Santa Fe, New Mexico USA
Discounted Abstract Deadline: Oct 16, 2018
Abstract Deadline: Oct 24, 2018
Scholarship Deadline: Oct 16, 2018
Discounted Registration Deadline: Nov 27, 2018

Sponsored by Gilead Sciences, Inc., Novo Nordisk A/S and Pfizer Inc.

Summary of Meeting:
The global prevalence of nonalcoholic fatty liver disease (NAFLD) has risen precipitously over the past two decades in parallel with the worldwide obesity epidemic; however, there are no approved therapies. The more advanced form of the disease, non-alcoholic steatohepatitis (NASH), is associated with progressive fibrosis and an increased risk of liver cancer. Despite the growing number of systemic and liver-specific abnormalities identified in patients with NAFLD, a clear hierarchy of the relative importance of specific defects has not emerged. Furthermore, a clear understanding of which individuals are at highest risk for progression to advanced liver disease and cancer remains elusive. Thus, the field lacks an integrated understanding of risk prediction, pathogenesis and validated biomarkers to predict or track disease progression without reliance on liver biopsies. Therefore, the goals of this conference are to: 1) Explore genetic and ethnic contributions to NAFLD development; 2) Clarify underlying pathogenic defects in NAFLD and NASH, focusing on the specific contributions of lipotoxicity, the microbiome, innate immune signaling and drivers of fibrosis; and 3) Highlight emerging prognostic and diagnostic biomarkers that are yielding new, more streamlined clinical trial designs to evaluate novel therapies. As a result of this conference, attendees should gain a more holistic understanding of the unmet needs and new paths to advancing our understanding of NAFLD pathogenesis, diagnosis and therapy. The multidisciplinary nature of the topics and speakers promises to generate novel insights that represent convergent expertise and opinion. In doing so, new paradigms are likely to emerge that greatly inform the expanding number of emerging diagnostic markers and therapeutic agents. The conference comes at a propitious time when there is already sufficient basic translational and clinical research to extract important new insights, focus on unmet needs and refine research strategies for the future.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Sunday, January 20 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, January 24 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, January 25 in order to fully experience the meeting.

SUNDAY, JANUARY 20

16:00—20:00
Arrival and Registration

Cava Santa Fe
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Cava Santa Fe

MONDAY, JANUARY 21

07:00—08:00
Breakfast

Anasazi Ballroom
08:00—09:00
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online.

Eldorado Grand Ballroom
* Scott L. Friedman, Icahn School of Medicine at Mount Sinai, USA

Gökhan S. Hotamisligil, Harvard School of Public Health, USA
Metainflammation and Fatty Liver Disease

09:00—11:45
Genetic / Ethnic Determinants and Natural History of NAFLD
Meeting has ended...abstracts no longer viewable online.

Eldorado Grand Ballroom
Stefano Romeo, University of Gothenburg, Sweden
Genetic Drivers of NAFLD

Coffee Break

* Arun J. Sanyal, Virginia Commonwealth University Medical Center, USA
The Dynamic Nature of NAFLD: A Critical Analysis of Disease Progression and Regression

Vincent WS Wong, Chinese University of Hong Kong, Hong Kong
NAFLD across the World – Similarities and Differences

Yanling Ma, National Institutes of Health, USA
Short Talk: A Novel Retinol Dehydrogenase, HSD17B13 Contributes to the Pathogenesis of Non-Alcoholic Fatty Liver Disease

Marlies Meisel, University of Pittsburgh, USA
Short Talk: Microbial Driven Inflammation is Associated with Hepatic Fibrosis in Tet2 Deficient Mice

Shuang Wang, Icahn School of Medicine at Mount Sinai, USA
Short Talk: Epigenomic Drivers of Hepatic Stellate Cell Activation in Fibrosis and NASH

11:45—17:00
On Own for Lunch

11:45—13:00
Poster Setup

Anasazi Ballroom
13:00—22:00
Poster Viewing

Anasazi Ballroom
14:30—16:30
Workshop 1: Biomarkers

Eldorado Grand Ballroom
* Yaron Rotman, NIDDK, National Institutes of Health, USA

Andrea Dennis, Perspectum Diagnostics, UK
Multi-Parametric MRI as A Composite Biomarker for NASH and NASH with Fibrosis

Shyam Sundhar Bale, Draper, USA
High-Throughput Microfluidic Microphysiological System to Recapitulate Hepatic Microenvironment

Loning Fu, Baylor College of Medicine, USA
Circadian Dysfunction Is an Independent Risk Factor for NAFLD and NASH

Eloy D. Hernandez, Genomics Institute of the Novartis Research Foundation, USA
Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis is Associated with Anti-Oxidative Gene Expression Profile in Rodents

Raquel Saborano, University of Birmingham, UK
How Can Stable Isotopic Tracer Studies Elucidate Metabolism in Liver Disease?

16:30—17:00
Coffee Available

Concourse
17:00—19:15
Metabolic Drivers of Cell Stress and Injury
Meeting has ended...abstracts no longer viewable online.

Eldorado Grand Ballroom
* Anna Mae Diehl, Duke University, USA

Harmeet Malhi, Mayo Clinic, USA
Lipotoxic Stress and the Pathogenesis of NASH

Michael Trauner, Medical University of Vienna, Austria
Bile Acid Regulation of Metabolism in the Development and Progression of NAFLD

Johan Auwerx, École Polytechnique Fédérale de Lausanne, Switzerland
A Novel Approach for NAD Boosting

Neha Bhat, Yale University, USA
Short Talk: Dyrk1b: A Novel Driver of Hepatic Lipid Metabolism

Mariana Acuna-Aravena, Weill Cornell Medical College, USA
Short Talk: Protective Role for Acot12 in the Pathogenesis of Hepatic Insulin Resistance and Nonalcoholic Fatty Liver Disease (NAFLD)

Victoria Slaughter, University of Central Florida, USA
Short Talk: Development and Characterization of A Two-Organ Human-on-a-Chip NAFLD Model

19:15—20:15
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Anasazi Ballroom
19:30—22:00
Poster Session 1

Anasazi Ballroom

TUESDAY, JANUARY 22

07:00—08:00
Breakfast

Anasazi Ballroom
08:00—11:00
Drivers and Consequences of Hepatic Lipotoxicity in NAFLD
Meeting has ended...abstracts no longer viewable online.

Eldorado Grand Ballroom
* Karen D. Corbin, AdventHealth, USA

Brent A. Tetri, St. Louis University, USA
Fatty Acid Dysregulation in NAFLD

Petra Hirsova, Mayo Clinic, USA
Sublethal Hepatocyte Injury as a Driver of Liver Inflammation in NASH

Coffee Break

Sheila Collins, Vanderbilt University Medical Center, USA
Metabolic Benefits from Activating Thermogenesis and Energy Expenditure

James P. Hardwick, Northeast Ohio Medical University, USA
Cytochrome P450-mediated Lipotoxicity

Paula J. Rote, Northeast Ohio Medical University, USA
Short Talk: Cytochrome P450 Fatty Acid Omega-Hydroxylase, Avenues for Fatty Acid Oxidation or Fatty Acid Synthesis in NAFLD Progression

Aline Mello, University of California, Davis, USA
Short Talk: Soluble Epoxide Hydrolase is a Potential Therapeutic Target for Non-Alcoholic Steatohepatitis

11:00—17:00
On Own for Lunch

11:00—13:00
Poster Setup

Anasazi Ballroom
13:00—22:00
Poster Viewing

Anasazi Ballroom
14:30—16:30
Workshop 2: Therapeutics

Eldorado Grand Ballroom
* Maria Elena Fuentes, Blade Therapeutics, USA

Anissa A. Widjaja, DUKE-NUS Medical School, Singapore
IL-11 is A Novel Therapeutic Target in Non-Alcoholic Steatohepatitis

Cecile Vernochet, Pfizer, USA
Validation of a Novel Human Adipocyte Anti-Lipolysis CRISPR-Based Screen

Wen-Wei Tsai, Ionis Pharmaceuticals, USA
Antisense-Mediated Reduction of Hepatic Autotaxin as a Potential Therapeutic Strategy for Non-Alcoholic Steatohepatitis

Maureen O'Connor, Forbius, USA
Development of AVID200, a TGF-β inhibitor with Optimal Isoform-Selectivity For Treatment of Fibrotic Diseases

Emily P. Offer, Redx Pharma, UK
ROCK2 Inhibitors for the Treatment of Fibrosis

Kyle S. McCommis, Washington University School of Medicine, USA
Mitochondrial Pyruvate Carrier Modulators to Treat Nonalcoholic Steatohepatitis

16:30—17:00
Coffee Available

Concourse
17:00—19:00
Innate Immune and Inflammatory Signaling
Meeting has ended...abstracts no longer viewable online.

Eldorado Grand Ballroom
* Anutosh Chakraborty, St. Louis University, USA

Gyongyi Szabo, University of Massachusetts Medical School, USA
Innate Immune Cell Activation in NASH: Mechanisms and Therapeutic Targets

Wajahat Z. Mehal, Yale University, USA
Innate Immune Signaling and NASH

Annie J. Kruger, MedStar Georgetown University Hospital, USA
Short Talk: Chemokine Receptor 2 and 5 Antagonism Attenuates Mouse Primary Hepatic Stellate Cell Activity and Prevents Skewing of Human Macrophages in a Co-Culture System

Svetlana Marukian, Axcella Health, USA
Short Talk: Unique Composition of Endogenous Modulators Impact Metabolic, Inflammation, and Fibrotic Markers in NAFLD/NASH Model Systems

Bishuang Cai, Columbia University, USA
Short Talk: The Role of MerTK and MerTK Cleavage in NASH-Related Liver Fibrosis

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Anasazi Ballroom
19:30—22:00
Poster Session 2

Anasazi Ballroom

WEDNESDAY, JANUARY 23

07:00—08:00
Breakfast

Anasazi Ballroom
08:00—11:15
Integrative and Systemic Biology of NAFLD
Meeting has ended...abstracts no longer viewable online.

Eldorado Grand Ballroom
* Brian N. Finck, Washington University School of Medicine, USA

Thomas P. Burris, Washington University School of Medicine, USA
Targeting Orphan Nuclear Receptors for Treatment of NASH

Noura S. Abul-Husn, Icahn School of Medicine at Mount Sinai, USA
Leveraging Genomics and Biobanks to Accelerate Drug Discovery in NASH

Coffee Break

Ira Tabas, Columbia University, USA
The Role of Hepatocyte TAZ in NASH and NASH-HCC

Ariel E. Feldstein, University of California, San Diego, USA
Extracellular Vesicles in NASH: From Contributors to Disease Pathogenesis to Novel Biomarkers

Kavita Jadhav, Columbia University, USA
Short Talk: Identifying The Role of Tribbles1 in Hepatic Lipogenesis

Srivatsan Kidambi, University of Nebraska, USA
Short Talk: Stiffness Induces NAFLD-like Metabolic Dysfunction in Primary Hepatocytes

Sebastian Prill, IMED Biotech Unit, AstraZeneca, Sweden
Short Talk: Inducing Liver Fat Accumulation in 3D Spheroids of Primary Human Hepatocytes: Towards a Human in vitro Model of NAFLD

11:15—17:00
On Own for Lunch

11:15—13:00
Poster Setup

Anasazi Ballroom
13:00—22:00
Poster Viewing

Anasazi Ballroom
16:30—17:00
Coffee Available

Concourse
17:00—19:15
Fibrosis and Cancer – Mechanisms and Markers
Meeting has ended...abstracts no longer viewable online.

Eldorado Grand Ballroom
* Harmeet Malhi, Mayo Clinic, USA

Scott L. Friedman, Icahn School of Medicine at Mount Sinai, USA
Hepatic Stellate Cells in Non-Alcoholic Steatohepatitis

Jelena Mann, Newcastle University, UK
Epigenetics of Fibrosis and Cancer in Liver Disease

Chinweike Ukomadu, Novartis Institutes for Biomedical Research, USA
BMP9 is a Pro-Fibrotic, Anti-Regenerative Factor in the Liver

Hongji Zhang, Ohio State University, USA
Short Talk: The Role of Neutrophil Extracellular Traps in Nonalcoholic Steatohepatitis-Associated Hepatocellular Carcinoma

Annelie Falkevall, Karolinska Institutet, Sweden
Short Talk: Reducing VEGF-B Signaling Ameliorates Hepatic Steatosis and Prevents Development of Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma

Brian Schwartz, Camp4 Therapeutics, USA
Gene Circuitry Mapping Identifies Novel Approaches for Reducing PNPLA3 148M Expression as a Treatment for NAFLD/NASH

19:15—20:15
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Anasazi Ballroom
19:30—22:00
Poster Session 3

Anasazi Ballroom

THURSDAY, JANUARY 24

07:00—08:00
Breakfast

Anasazi Ballroom
08:00—11:15
Modalities of NAFLD Diagnosis and Prognosis Assessment
Meeting has ended...abstracts no longer viewable online.

Eldorado Grand Ballroom
* Mary E. Rinella, Northwestern University, USA

Shusuke Toden, Molecular Stethoscope, USA
Whole-Transcriptome Circulating Cell-Free mRNA Analysis to Diagnose and Stratify NAFLD

Rohit Loomba, University of California, San Diego, Salk Institute, USA
Serum and Imaging Biomarkers

Coffee Break

Gabe A. Kwong, Glympse Bio, USA
Assessing Matrix Turnover and Proteolysis

Yi Luo, Bristol-Myers Squibb, USA
Identification of Serum Biomarkers of Advanced Fibrosis in NASH Patients

Lars Verschuren, TNO, Netherlands
Short Talk: Identification and Verification of Human Biomarkers for Early Detection of NASH-Induced Fibrosis

Madhulika Tripathi, Duke-NUS Medical School Singapore, Singapore
Short Talk: Role of YAP (Yes-Associated Protein) in Regulating FGF21 Expression during NAFLD Progression

Yaron Rotman, NIDDK, National Institutes of Health, USA
Short Talk: Human and Murine Studies Identify RORA as a Modulator of Steatosis and Severity of Non-Alcoholic Fatty Liver Disease

11:15—17:00
On Own for Lunch

14:30—16:30
Workshop 3: Animal Models

Eldorado Grand Ballroom
* Henrik H. Hansen, Gubra, Denmark
A Novel Gubra Amylin NASH (GAN) Diet-Induced ob/ob Mouse Model Of Biopsy-Confirmed Non-Alcoholic Steatohepatitis

Roeland Hanemaaijer, TNO, Netherlands
Development of a Diet-Induced Disease-Mimicking in vitro Model of Non-Alcoholic Steatohepatitis (NASH)/Fibrosis

Julia Nilsson, Lund University, Sweden
The NIF Mouse - A New and Unique Model of NASH

Alexander W. Coutts, Recombinetics, Inc., USA
A PNPLA3I148M Gene-Edited Ossabaw Swine Model of Nonalcoholic Steatohepatitis (NASH)

Henry N. Ginsberg, Columbia University College of Physicians and Surgeons, USA
Hepatocyte-Specific Depletion of Nuclear Membrane Proteins LAP1 or torsinA Causes Nonalcoholic Steatohepatitis with Decreased VLDL Secretion and Abnormal Lipid Droplet Accumulation in Chow Fed Mice

Raul C. Camacho, Janssen, USA
Non-Alcoholic Steatohepatitis (NASH) Is Inducible by Adding Fructose to a High Fat/Cholesterol Diet in Cynomolgus Monkeys

16:30—17:00
Coffee Available

Concourse
17:00—18:45
Clinical Trial Design and Emerging Therapies
Meeting has ended...abstracts no longer viewable online.

Eldorado Grand Ballroom
* Brent A. Tetri, St. Louis University, USA

Mary E. Rinella, Northwestern University, USA
Clinical Trial Design, Endpoints and Regulatory Science in NAFLD Accelerating Patient Accrual and Shortening Trial Length

Manal F. Abdelmalek, Duke University Medical Center, USA
Emerging Therapies for the Treatment of NASH

Daniel Edward Lefever, University of Pittsburgh, USA
Short Talk: A Quantitative Systems Pharmacology (QSP) Approach to Repurposing Drugs for Non-Alcoholic Fatty Liver Disease (NAFLD)

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions
Meeting has ended...abstracts no longer viewable online.

Eldorado Grand Ballroom
* Arun J. Sanyal, Virginia Commonwealth University Medical Center, USA

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Anasazi Ballroom
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Anasazi Ballroom

FRIDAY, JANUARY 25

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Gilead Sciences, Inc. Novo Nordisk A/S
Pfizer Inc.
 

We gratefully acknowledge additional support from these exhibitors at this conference:

AstraZeneca
Please stop by to meet these exhibitors during the conference.


We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1 R13 DK118909-01

Funding for this conference was made possible (in part) by 1 R13 DK118909-01 from NIDDK at the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional support for this conference from:

GENFIT SA Hanmi Pharmaceuticals
InSphero Inc. Research Diets, Inc.

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Bristol-Myers Squibb Company


Novartis Institutes for BioMedical Research


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org,
Phone:+1 970-262-1179